Do rosuvastatin and fenofibrate cause erectile dysfunction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Rosuvastatin and Fenofibrate Do Not Directly Cause Erectile Dysfunction, Though Rosuvastatin Shows Conflicting Evidence

Neither rosuvastatin nor fenofibrate are established causes of erectile dysfunction based on current clinical guidelines and FDA labeling, though emerging research suggests rosuvastatin may have a modest association while fenofibrate appears neutral or potentially beneficial.

Evidence Hierarchy and Key Findings

FDA Drug Labels (Highest Priority)

The FDA-approved labeling for both medications does not list erectile dysfunction as a recognized adverse effect 1, 2. The rosuvastatin label extensively details drug interactions and adverse events but makes no mention of sexual dysfunction 1. Similarly, fenofibrate labeling discusses numerous side effects without identifying ED as a concern 2.

Clinical Practice Guidelines

Multiple authoritative guidelines addressing erectile dysfunction fail to identify statins or fibrates as causative agents:

  • The 2018 AUA Guideline comprehensively discusses ED risk factors and treatments but does not list statins or fibrates as causes 3
  • The 2025 AHA/ACC Hypertension Guideline specifically addresses sexual dysfunction in hypertensive patients, noting that diuretics and beta-blockers (except nebivolol) are most commonly associated with ED in men, while ARBs have the most favorable profile 4. Statins are not mentioned as problematic
  • The 2003 AACE Guidelines detail drug-related causes of ED extensively, listing antihypertensives, psychotropic drugs, and specific agents like spironolactone and cimetidine, but do not include statins or fibrates 5

Drug Interaction Guidelines

The 2016 AHA Scientific Statement on statin drug interactions addresses the combination of statins with fibrates, focusing on myopathy risk rather than sexual dysfunction 6. When fenofibrate is combined with rosuvastatin, the concern is muscle toxicity, not ED. The statement recommends fenofibrate over gemfibrozil when combining with statins due to lower interaction risk 6.

Emerging Research Evidence (Mixed and Conflicting)

Rosuvastatin-Specific Studies

Recent research presents contradictory findings:

Evidence suggesting harm:

  • A 2026 Mendelian randomization study found lipophilic statins (atorvastatin, simvastatin) causally increased ED risk, but rosuvastatin (hydrophilic) showed no causal relationship (P=0.428) 7
  • A 2026 pharmacovigilance study identified both atorvastatin (ROR=3.36) and rosuvastatin (ROR=3.22) as significantly linked to ED through disproportionality analysis, implicating dysregulated inflammatory and immunofibrotic remodeling 8
  • A 2025 NHANES analysis found statin use associated with ED (OR=1.77,95% CI: 1.34-2.35) after adjustments, though this did not differentiate between statin types 9

Evidence suggesting no harm:

  • The 2018 HOPE-3 trial (5.8-year follow-up, 2,153 men) found rosuvastatin 10 mg daily caused no change in erectile function compared to placebo using validated IIEF-EF scores (P=0.74) 10
  • A 2016 case series in diabetic men showed rosuvastatin decreased free testosterone levels but SHIM scores (sexual function) did not differ (16.3±4.8 vs 16.0±4.9, P=0.944) 11

Fenofibrate-Specific Studies

Evidence for fenofibrate is more favorable:

  • A 2025 in vitro study demonstrated gemfibrozil (a related fibrate) caused dose-dependent relaxation in mouse corpus cavernosum tissues via endothelial nitric oxide, suggesting potential beneficial effects on erectile function 12
  • A 2002 systematic review identified fibrates as a source of ED based on case reports and regulatory agency data, though the evidence quality was limited 13

Clinical Context and Interpretation

The Underlying Disease vs. The Drug

Critical caveat: Men requiring statins and fibrates typically have cardiovascular risk factors (diabetes, hypertension, dyslipidemia, obesity) that independently cause ED through endothelial dysfunction and atherosclerosis 5. The 2003 AACE Guidelines emphasize that ED shares common risk factors with cardiovascular disease and may be a predictor of future cardiac events 5.

Mechanism Considerations

When ED occurs in patients on these medications, consider:

  1. Vascular disease progression (the primary driver in most cases)
  2. Concomitant medications with established ED risk (beta-blockers, diuretics) 4
  3. Testosterone reduction (documented with rosuvastatin but without functional impact) 11
  4. Psychological factors and performance anxiety 5

Practical Clinical Approach

If a patient on rosuvastatin or fenofibrate develops ED:

  1. Do not automatically discontinue these medications, as cardiovascular benefits far outweigh uncertain ED risk
  2. Evaluate other medications first—prioritize stopping or switching beta-blockers (except nebivolol) or diuretics if present 4
  3. Assess cardiovascular risk factors and optimize diabetes, hypertension, and smoking cessation 5
  4. Initiate PDE-5 inhibitor therapy (sildenafil, tadalafil, vardenafil, avanafil) as first-line ED treatment 14, 3
  5. Consider switching rosuvastatin to another statin only if other interventions fail and temporal relationship is clear
  6. Continue fenofibrate without concern, as evidence suggests neutral or beneficial effects 12

PDE-5 Inhibitor Safety

PDE-5 inhibitors can be safely coadministered with statins and fibrates 4. The 2025 AHA/ACC guideline confirms these drugs are safe with antihypertensives, though caution is needed with CYP3A4 inhibitors (diltiazem, verapamil) and they are contraindicated with nitrates 4.

Bottom Line

The weight of guideline-level evidence and FDA labeling does not support rosuvastatin or fenofibrate as causes of erectile dysfunction. While emerging observational and mechanistic research raises questions about rosuvastatin specifically, the highest-quality randomized trial (HOPE-3) found no effect 10. The Canadian consensus statement on statin adverse effects notes conflicting data on ED, suggesting statins may even be protective through improved endothelial function 15. Continue these medications for their proven cardiovascular benefits and treat ED with PDE-5 inhibitors as first-line therapy 14, 3.

References

3
Guideline

erectile dysfunction: aua guideline.

The Journal of urology, 2018

5
Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2003

Related Questions

Can Hydrochlorothiazide (HCTZ) cause erectile dysfunction?
A 63-year-old woman taking lisinopril 40 mg, hydrochlorothiazide 25 mg, amlodipine 10 mg, metformin 500 mg, and rosuvastatin 10 mg had her blood pressure improve from 158/94 mmHg to 130/82 mmHg and now reports a brief episode of dizziness—what is the most likely cause of the dizziness and how should her antihypertensive regimen be managed?
How should I manage a patient with moderate peripheral artery disease who presents with leg swelling?
In an adult who is vomiting and cannot take oral medication, what rectal options can be used for constipation and fever management?
How should quetiapine be initiated and monitored in a patient with atrial fibrillation and dementia?
In a 54‑year‑old female with bipolar II disorder, recurrent major depressive disorder, generalized anxiety disorder, psychophysiologic insomnia, vitamin D deficiency, cognitive communication deficit, drug‑induced subacute dyskinesia, and a history of unspecified convulsions who is currently taking lamotrigine 200 mg daily, sertraline 75 mg daily, buspirone 5 mg twice daily, Austedo (deutetrabenazine) 18 mg twice daily titrated toward 48 mg/day, and topiramate 50 mg twice daily, and who will discontinue Auvelity (dextromethorphan‑bupropion), what alternative medication(s) can be used to control her major depressive disorder symptoms, and should Klonopin (clonazepam) be started?
What is the appropriate management for constant picking and pulling behavior in a patient with vascular dementia?
What medications are recommended to treat compulsive picking and pulling behaviors in an older adult with vascular dementia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.